LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

Search

Becton Dickinson and Co

Fermé

Secteur Soins de santé

231.73 -0.94

Résumé

Variation du prix de l'action

24h

Actuel

Min

229.67

Max

235.4

Chiffres clés

By Trading Economics

Revenu

255M

537M

Ventes

344M

5.1B

P/E

Moyenne du Secteur

56.75

79.786

BPA

3.17

Marge bénéficiaire

10.634

Employés

73,000

EBITDA

215M

1.3B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+19.63 upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2024

Date du Prochain Dividende

27 sept. 2024

Date du Prochain Détachement de Dividende

5 sept. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-390M

66B

Ouverture précédente

232.67

Clôture précédente

231.73

Sentiment de l'Actualité

By Acuity

63%

37%

319 / 369 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Becton Dickinson and Co Graphique

Actualités Associées

3 juin 2024, 11:18 UTC

Acquisitions, Fusions, Rachats

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

2 mai 2024, 11:07 UTC

Résultats

Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings

1 févr. 2024, 12:04 UTC

Résultats

Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q

4 juin 2024, 17:26 UTC

Acquisitions, Fusions, Rachats

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 juin 2024, 15:30 UTC

Actions en Tendance

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3 juin 2024, 13:26 UTC

Acquisitions, Fusions, Rachats

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 juin 2024, 12:25 UTC

Actualités
Acquisitions, Fusions, Rachats

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3 juin 2024, 11:03 UTC

Actualités
Acquisitions, Fusions, Rachats

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3 juin 2024, 10:40 UTC

Acquisitions, Fusions, Rachats

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3 juin 2024, 10:32 UTC

Acquisitions, Fusions, Rachats

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3 juin 2024, 10:31 UTC

Acquisitions, Fusions, Rachats

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3 juin 2024, 10:31 UTC

Acquisitions, Fusions, Rachats

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3 juin 2024, 10:30 UTC

Acquisitions, Fusions, Rachats

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3 juin 2024, 10:30 UTC

Acquisitions, Fusions, Rachats

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

2 mai 2024, 10:35 UTC

Résultats

Becton Dickinson Had Seen FY24 Adjusted EPS $12.82-$13.06 >BDX

2 mai 2024, 10:34 UTC

Résultats

Becton Dickinson Raises FY24 View To Adj EPS $12.95-Adj EPS $13.15 >BDX

2 mai 2024, 10:34 UTC

Résultats

Becton Dickinson Still Sees FY24 Organic Revenue Growth of 5.5%-6.25% >BDX

2 mai 2024, 10:33 UTC

Résultats

Becton Dickinson Had Seen FY24 Revenue $20.2B-$20.4B >BDX

2 mai 2024, 10:33 UTC

Résultats

Becton Dickinson Cuts FY24 View To Rev $20.1B-$20.3B >BDX

2 mai 2024, 10:30 UTC

Résultats

Becton Dickinson 2Q Net $537M >BDX

2 mai 2024, 10:30 UTC

Résultats

Becton Dickinson 2Q Adj EPS $3.17 >BDX

2 mai 2024, 10:30 UTC

Résultats

Becton Dickinson 2Q EPS $1.85 >BDX

2 mai 2024, 10:30 UTC

Résultats

Becton Dickinson 2Q Rev $5B >BDX

27 mars 2024, 21:59 UTC

Acquisitions, Fusions, Rachats

3M's Healthcare Spinoff Stock Fell. This Is What It's Worth. -- Barrons.com

27 mars 2024, 09:15 UTC

Acquisitions, Fusions, Rachats

3M's Healthcare Spinoff Stock Is Trading. This Is What It's Worth. -- Barrons.com

1 févr. 2024, 11:34 UTC

Résultats

Becton Dickinson Sees FY24 Currency-Neutral Rev Growth 4.75%-5.5% >BDX

1 févr. 2024, 11:33 UTC

Résultats

Becton Dickinson Sees FY24 Organic Rev Growth 5.5%-6.25% >BDX

1 févr. 2024, 11:30 UTC

Résultats

Becton Dickinson 1Q Net $281M >BDX

1 févr. 2024, 11:30 UTC

Résultats

Becton Dickinson Sees FY Adj EPS $12.82-Adj EPS $13.06 >BDX

1 févr. 2024, 11:30 UTC

Résultats

Becton Dickinson 1Q EPS 96c >BDX

Comparaison

Variation de prix

Becton Dickinson and Co prévision

Objectif de Prix

By TipRanks

19.63% hausse

Prévisions sur 12 Mois

Moyen 280 USD  19.63%

Haut 312 USD

Bas 255 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

8

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

225.97 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

319 / 369Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through segments such as BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.